Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fast TILs in Metastatic Cancer With Pleural Disease
NCT07192900Phase 1Recruiting
- Start
- Jun 2026
- Primary completion
- Apr 2033
- Modality
- Monoclonal Antibodies, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of GC101 TIL + pembrolizumab in malignant pleural effusion (MPE), malignant mesothelioma and Secondary malignant neoplasm of pleura. Primary endpoints: Feasibility of local manufacture of ACT product from drained pleural effusions using the CliniMACS Prodigy device at 30 days and Safety of intrapleural administration of the locally manufactured ACT product plus Interleukin 2 (IL-2) at 5 years. Started Jun 2026; status: recruiting.
02
Drugs
GC101 TIL + pembrolizumab
03
Conditions
malignant pleural effusion (MPE)malignant mesotheliomaSecondary malignant neoplasm of pleura
Beyond the preview
Go deeper on NCT07192900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07192900.